Oyster Point Pharma, Inc. (OYST) 是一家上市公司 屬於 醫療保健 板塊，經營於 生物科技 產業. 公司總部位於 Princeton, NJ, 美国. 現任CEO為 Jeffrey Nau.
OYST 擁有 IPO日期為 2019-10-31, 303 名全職員工, 在 NASDAQ Global Select.
As of January 3, 2023, Oyster Point Pharma, Inc. was acquired by Viatris Inc. Oyster Point Pharma, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical therapies to treat ophthalmic diseases in the United States. The company's product candidate is TYRVAYA, a nicotinic acetylcholine receptor agonist for the treatment of signs and symptoms of dry eye disease. It is also developing TYRVAYA that is in Phase II clinical trial for the treatment of for neurotrophic keratopathy. The company was incorporated in 2015 and is headquartered in Princeton, New Jersey.
